SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (Pichia pastoris), as a suitable vaccine candidate agains...
Main Authors: | Jeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, Brian Keegan, Bin Zhan, Junfei Wei, Zhuyun Liu, Jungsoon Lee, Rahki Kundu, Rakesh Adhikari, Cristina Poveda, Maria Jose Villar, Ana Carolina de Araujo Leao, Joanne Altieri Rivera, Zoha Momin, Portia M. Gillespie, Jason T. Kimata, Ulrich Strych, Peter J. Hotez, Maria Elena Bottazzi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-08-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2021.1901545 |
Similar Items
-
A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay
by: Gaetano Donofrio, et al.
Published: (2021-04-01) -
Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-2
by: Davide Gentile, et al.
Published: (2024-02-01) -
Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development
by: Sheng-Wen Huang, et al.
Published: (2020-08-01) -
Silver nanoparticles with excellent biocompatibility block pseudotyped SARS-CoV-2 in the presence of lung surfactant
by: Govind Gupta, et al.
Published: (2022-12-01) -
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
by: Jianhui Nie, et al.
Published: (2020-01-01)